1;Radiotherapy for Hodgkin Lymphoma;1 1.1;Preface;4 1.2;Contents;6 1.3;1: History of Radiotherapy of Hodgkin's Disease (Now Hodgkin Lymphoma);8 1.3.1;1.1 Introduction;8 1.3.2;1.2 Radiotherapy as a Curative Treatment Modality;10 1.3.3;1.3 Radiotherapy as Part of Combined Modality Treatment;11 1.3.4;References;12 1.4;2: Background and Rationale for Radiotherapy in Early-Stage Hodgkin Lymphoma;14 1.4.1;2.1 Introduction;14 1.4.2;2.2 Combined Modality Therapy for Early-Stage Hodgkin Lymphoma;15 1.4.2.1;2.2.1 Radiation Dose and Fractionation;16 1.4.2.2;2.2.2 Radiation Field Size;16 1.4.2.3;2.2.3 Association of Radiation Dose/Field Size and Late Toxicity;18 1.4.3;2.3 Can Radiation Therapy Be Safely Eliminated in Early-Stage Hodgkin Lymphoma?;19 1.4.3.1;2.3.1 Trials Comparing Combined Modality Therapy Versus Chemotherapy Alone;19 1.4.3.2;2.3.2 Trials of Early PET Scans for Selecting Patients for Omission of Radiotherapy;24 1.4.3.3;2.3.3 Patterns of Failure After Chemotherapy for Early-Stage Hodgkin Lymphoma;24 1.4.4;2.4 Conclusion;25 1.4.5;References;25 1.5;3: Background and Rationale for Radiotherapy in Advanced-Stage Hodgkin Lymphoma;28 1.5.1;3.1 Historical Context, Treatment of Advanced Disease with Radiation Therapy Alone;28 1.5.2;3.2 Summary of the Literature on Advanced-Stage Hodgkin Lymphoma;29 1.5.2.1;3.2.1 GELA;32 1.5.2.2;3.2.2 EORTC;32 1.5.2.3;3.2.3 GHSG;32 1.5.2.4;3.2.4 Stanford;33 1.5.3;3.3 Current Opinion;34 1.5.3.1;3.3.1 Treatment Recommendations Advanced-Stage Hodgkin Lymphoma;34 1.5.4;3.4 Future;34 1.5.5;References;35 1.6;4: Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma;37 1.6.1;4.1 Introduction;37 1.6.2;4.2 Salvage After Radiotherapy Alone;37 1.6.3;4.3 Salvage of Patients Who Relapse or Remain Refractory After Chemotherapy Alone or Combined-Modality Therapy;39 1.6.4;4.4 Salvage with Radiation Alone;39 1.6.5;4.5 Salvage of Systemic Chemotherapy Failures with Standard-Dose Chemotherapy Regimen;41 1.6.6;4.6 High-Dose Therapy (HDT) and Autologous Stem-Cell Transplantation;41 1.6.6.1;4.6.1 The Randomized Trials;41 1.6.6.2;4.6.2 Standard-Dose Salvage Prior to HDT/ASCT;42 1.6.6.3;4.6.3 High-Dose Therapy Regimens and Stem-Cell Source;42 1.6.6.4;4.6.4 Predictive Factors of HDT/ASCT Salvage Outcome;43 1.6.6.5;4.6.5 Incorporation of Radiotherapy into HDT/ASCT Programs;44 1.6.6.6;4.6.6 Salvage After ASCT Failure;46 1.6.7;4.7 Role of RT in Local Control and Palliation;46 1.6.8;4.8 Conclusion;47 1.6.9;References;47 1.7;5: Principles of Chemotherapy in Hodgkin Lymphoma;51 1.7.1;5.1 Introduction;51 1.7.2;5.2 Common Chemotherapy Regimens in Classical Hodgkin Lymphoma;52 1.7.2.1;5.2.1 MOPP Chemotherapy;52 1.7.2.1.1;5.2.1.1 Side-Effect Profile;52 1.7.2.1.2;5.2.1.2 Long-Term Side Effects of MOPP;52 1.7.2.2;5.2.2 ABVD;53 1.7.2.2.1;5.2.2.1 Side-Effect Profile;53 1.7.2.3;5.2.3 BEACOPP;54 1.7.2.3.1;5.2.3.1 Acute Side Effects;55 1.7.2.4;5.2.4 Stanford V;55 1.7.2.5;5.2.5 Rituximab;56 1.7.2.6;5.2.6 Bendamustine;56 1.7.2.7;5.2.7 SGN-35;56 1.7.3;5.3 Late Side Effects of Chemotherapy;57 1.7.3.1;5.3.1 Myelodysplasia and Acute Myeloid Leukemia;57 1.7.3.2;5.3.2 Non-Hodgkin Lymphoma;57 1.7.3.3;5.3.3 Solid Tumors;57 1.7.4;5.4 Follow-Up;57 1.7.5;References;58 1.8;6: Management of Lymphocyte Predominant Hodgkin Lymphoma;59 1.8.1;6.1 Introduction;59 1.8.2;6.2 Histopathology;60 1.8.3;6.3 Clinical Presentation;61 1.8.4;6.4 Diagnosis and Staging Work-Up;62 1.8.5;6.5 Treatment and Outcomes for Stage I/II Disease;62 1.8.5.1;6.5.1 Outcomes from Combined-Modality Treatment;63 1.8.5.2;6.5.2 Role of Chemotherapy in the Treatment of Stage I/II Disease;63 1.8.5.3;6.5.3 RT Technique;66 1.8.5.4;6.5.4 Treatment-Related Complications;67 1.8.5.5;6.5.5 Observation or Minimal Treatment After Surgical Resection;67 1.8.6;6.6 Treatment and Outcomes for Stage III/IV Disease;68 1.8.7;6.7 Role of Monoclonal Antibody Therapy for LPHL;69 1.8.8;6.8 Follow-Up After Treatment Completion;69 1.8.9;6.9 Treatment and Outcomes for Recurrent Disease;69 1.8.10;6.10 Conclusio